EAM
CRBP icon

Exome Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Exome Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.2M Buy
234,136
+94,593
+68% +$796K 1.14% 38
2025
Q4 		$1.14M Sell
139,543
-90,419
-39% -$1.12M 0.54% 51
2025
Q3 		$2.91M Sell
229,962
-47,355
-17% -$450K 1.76% 20
2025
Q2 		$1.91M Sell
277,317
-12,373
-4% -$89.9K 1.42% 29
2025
Q1 		$1.54M Buy
+289,690
New +$2.56M 1.37% 34
2024
Q3 		– Sell
-84,790
Closed -$3.84M – 67
2024
Q2 		$3.84M Sell
84,790
-3,056
-3% -$129K 3.42% 6
2024
Q1 		$3.45M Buy
+87,846
New +$2.17M 2.95% 8

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Exome Asset Management's CRBP Position: Q1 2026 in Review

Exome Asset Management increased its Corbus Pharmaceuticals (CRBP) stake by 68% in Q1 2026, buying an estimated $796K and bringing the position to 234,136 shares worth $2.2M. The position accounts for 1.14% of the portfolio, ranked #38.

Exome Asset Management first reported a position in CRBP in Q1 2024 and has held it in 7 quarters since. The position peaked at $3.84M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Exome Asset Management held 234,136 shares of Corbus Pharmaceuticals worth $2.2M as of Q1 2026.
  • Exome Asset Management bought 94,593 Corbus Pharmaceuticals shares in Q1 2026, an estimated $796K.
  • Corbus Pharmaceuticals made up 1.14% of Exome Asset Management's portfolio in Q1 2026, its #38 holding.
  • Exome Asset Management first reported a position in Corbus Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
  • Exome Asset Management's Corbus Pharmaceuticals position peaked at $3.84M in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.